Kid Risk, Inc., Orlando, Florida Delft University of Technology, Delft, The Netherlands; and.
Kid Risk, Inc., Orlando, Florida.
J Infect Dis. 2014 Nov 1;210 Suppl 1:S398-411. doi: 10.1093/infdis/jit844.
India presented many challenges to the global effort to eliminate the transmission of wild polioviruses (WPVs) and poliomyelitis, with the last case of WPV type 2 in the world reported in northern India in 1999 and WPV types 1 and 3 circulating until early 2011.
We used a differential equation-based model to characterize the dynamics of poliovirus transmission and various opportunities to increase and maintain high population immunity to poliovirus transmission for 2 high-risk areas in northern India. We explored options that India probably considered before 2011, to demonstrate the impact of strategies to accelerate WPV elimination and sustain high population immunity. We also characterized the impact of current and potential future vaccination strategies and explored the potential trade-offs associated with the various strategies.
National immunization policy choices impact population immunity, which leads to different numbers of expected paralytic cases and risks of circulating vaccine-derived poliovirus outbreaks. Assuming that India maintains high vaccination intensity everywhere, we do not anticipate issues with outbreaks of circulating vaccine-derived poliovirus type 2 infection following globally coordinated cessation of type 2-containting oral poliovirus vaccine use. We find a relatively modest potential role for inactivated poliovirus vaccine.
National policy makers should consider the impacts of their vaccine choices on population immunity to poliovirus transmission.
印度在全球消除野生脊髓灰质炎病毒(WPV)和脊髓灰质炎的努力中面临诸多挑战,世界上最后一例 WPV 2 型病例于 1999 年在印度北部报告,WPV 1 型和 3 型直到 2011 年初仍在传播。
我们使用基于微分方程的模型来描述印度北部两个高风险地区脊髓灰质炎病毒传播的动态以及增加和维持高人群对脊髓灰质炎病毒传播的免疫力的各种机会。我们探讨了印度在 2011 年之前可能考虑过的选择,以展示加速 WPV 消除和维持高人群免疫力的策略的影响。我们还描述了当前和潜在未来疫苗接种策略的影响,并探讨了与各种策略相关的潜在权衡。
国家免疫政策选择会影响人群免疫力,从而导致预期麻痹病例数量和循环疫苗衍生脊髓灰质炎病毒爆发风险的不同。假设印度在所有地方都保持高疫苗接种强度,我们预计在全球协调停止使用含 2 型脊髓灰质炎病毒的口服脊髓灰质炎疫苗后,不会出现循环疫苗衍生脊髓灰质炎病毒 2 型感染的爆发问题。我们发现灭活脊髓灰质炎病毒疫苗的作用相对较小。
国家政策制定者应考虑其疫苗选择对人群对脊髓灰质炎病毒传播的免疫力的影响。